MedTrace Logo

Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)

NCT00988260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this study is to find the optimal dose of Org 37462 for Japanese females undergoing controlled ovarian stimulation for in vitro fertilization intracytoplasmic sperm injection (IVF-ICSI).

Conditions

  • Controlled Ovarian Stimulation

Interventions

DRUG

Ganirelix

Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days

DRUG

Ganirelix

Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days

DRUG

Ganirelix

Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-03
Primary Completion
2004-04-12
Completion
2004-04-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988260 on ClinicalTrials.gov